OBJECTIVES: We sought to compare prevalence and determinants of multidrug-resistant tuberculosis (MDR-TB) between tuberculosis patients in Baja California, Mexico, and Hispanic patients in California. METHODS: Using data from Mexico's National TB Drug Resistance Survey (2008-2009) and California Department of Public Health TB case registry (2004-2009), we assessed differences in MDR-TB prevalence comparing (1) Mexicans in Baja California, (2) Mexico-born Hispanics in California, (3) US-born Hispanics in California, and (4) California Hispanics born elsewhere. RESULTS: MDR-TB prevalence was 2.1% in Baja California patients, 1.6% in Mexico-born California patients, 0.4% in US-born California patients, and 2.7% in Hispanic California patients born elsewhere. In multivariate analysis, previous antituberculosis treatment was associated with MDR-TB (odds ratio [OR] = 6.57; 95% confidence interval [CI] = 3.34, 12.96); Mexico-born TB patients in California (OR = 5.08; 95% CI = 1.19, 21.75) and those born elsewhere (OR = 7.69; 95% CI = 1.71, 34.67) had greater odds of MDR-TB compared with US-born patients (reference category). CONCLUSIONS: Hispanic patients born outside the US or Mexico were more likely to have MDR-TB than were those born within these countries. Possible explanations include different levels of exposure to resistant strains and inadequate treatment.
OBJECTIVES: We sought to compare prevalence and determinants of multidrug-resistant tuberculosis (MDR-TB) between tuberculosispatients in Baja California, Mexico, and Hispanic patients in California. METHODS: Using data from Mexico's National TB Drug Resistance Survey (2008-2009) and California Department of Public Health TB case registry (2004-2009), we assessed differences in MDR-TB prevalence comparing (1) Mexicans in Baja California, (2) Mexico-born Hispanics in California, (3) US-born Hispanics in California, and (4) California Hispanics born elsewhere. RESULTS: MDR-TB prevalence was 2.1% in Baja Californiapatients, 1.6% in Mexico-born Californiapatients, 0.4% in US-born Californiapatients, and 2.7% in Hispanic Californiapatients born elsewhere. In multivariate analysis, previous antituberculosis treatment was associated with MDR-TB (odds ratio [OR] = 6.57; 95% confidence interval [CI] = 3.34, 12.96); Mexico-born TB patients in California (OR = 5.08; 95% CI = 1.19, 21.75) and those born elsewhere (OR = 7.69; 95% CI = 1.71, 34.67) had greater odds of MDR-TB compared with US-born patients (reference category). CONCLUSIONS: Hispanic patients born outside the US or Mexico were more likely to have MDR-TB than were those born within these countries. Possible explanations include different levels of exposure to resistant strains and inadequate treatment.
Authors: M L García-García; M E Jiménez-Corona; A Ponce-de-León; A Jiménez-Corona; M Palacios-Martínez; S Balandrano-Campos; L Ferreyra-Reyes; L Juárez-Sandino; J Sifuentes-Osornio; H Olivera-Díaz; J L Valdespino-Gómez; P M Small Journal: Int J Tuberc Lung Dis Date: 2000-12 Impact factor: 2.373
Authors: I Bojorquez-Chapela; C E Bäcker; I Orejel; A López; A Díaz-Quiñonez; M I Hernández-Serrato; S Balandrano; M Romero; M M Téllez-Rojo Solís; M Castellanos; C Alpuche; M Hernández-Ávila; H López-Gatell Journal: Int J Tuberc Lung Dis Date: 2013-04 Impact factor: 2.373
Authors: R Laniado-Laborín; J Estrada-Guzman; H Perez; F Batiz-Armenta; J M Alcantar-Schramm Journal: Int J Tuberc Lung Dis Date: 2012-03-07 Impact factor: 2.373
Authors: Susan P Fisher-Hoch; Erin Whitney; Joseph B McCormick; Gonzalo Crespo; Brian Smith; Mohammad H Rahbar; Blanca I Restrepo Journal: Scand J Infect Dis Date: 2008